Releases - DiaGenic ASA

View:

2008

 

Found press releases

 

FINANCIAL CALENDER FOR 2009

11/19/2008 9:30 AM EST
- 4th quarter results 2008 and preliminary annual result for 2008: 19 February 2009 - 1st quarter results 2009: 14 May 2009 - Annual General Meeting: 4 June 2009 - 2nd quarter results 2009: 21 August 2009 - 3rd quarter results 2009: 30 October 2009 This information is subject to disclosure requirements according to §5-12 vphl (Norwegian Securities Trading Act)

PRODUCT LAUNCH IN INDIA

11/10/2008 2:00 AM EST
DiaGenic and Super Religare Laboratories (SRL) have launched the breast cancer test BCtect™ in the Indian market. The launch took place on the 8th November at the Royal Norwegian Embassy in Delhi.

During her address, the Norwegian ambassador, Mrs Ann Ollestad, said “Representing Norway in India on a day where we together can present a new and revolutionary test for early breast cancer detection is a great...

REPORT FOR THIRD QUARTER 2008

10/31/2008 3:00 AM EST
The third quarter report for 2008 was approved by the Board of Directors on October 30th. Please find the report and an investor presentation enclosed.

Highlights from the report:
- Breast cancer test BCtect™ approved by Super Religare Laboratories Ltd (SRL)
- Commercial launch of BCtect™ in India scheduled for 8 November 2008
- Research grant awarded by the EU Commission
- New patents for Japan, New...

DIAGENIC PARTNERS WITH DNAVision TO OFFER FIRST BREAST CANCER AND ALZHEIMER’S GE...

10/28/2008 6:00 AM EST
OSLO. – November 28 2008 –DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services. With this laboratory service and following CE marking scheduled in early 2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression...

PRESENTATION OF THE THIRD QUARTER REPORT 2008

10/24/2008 5:15 AM EST
Presentation of the third quarter report will take place 08:30 (Norwegian time), Friday 31 October at DiaGenic ASA, Grenseveien 92 (Helsfyr), Oslo. The presentation will be available on webcast with the following link: http://media01.smartcom.no/Microsite/start.aspx?eventid=3595 After the presentation the webcast will be available on demand on the webpage www.diagenic.com under `Investor relations`.

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

10/13/2008 10:50 AM EST
On October 13 2008 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The transactions made no changes in the net exposure among the insiders. The transactions are described in more detail below.

Director and board member Praveen Sharma has redeemed the forward contract for 300,000 shares entered into on September 23 2008 at a forward price of NOK 3.135 per share, through the...

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

9/24/2008 4:10 AM EST
On September 24 2008 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The transactions made no changes in the net exposure among the insiders. The transactions are described in more detail below.

Director and board member Praveen Sharma has entered into a 6 months forward contract selling 300,000 shares at NOK 3.85 per share, and purchase of 300,000 shares at NOK 4.046 per...

DIAGENIC’s TEST FOR BREAST CANCER TO BE LAUNCHED IN INDIA ON THE 8th NOVEMBER 20...

9/23/2008 6:15 AM EST
DiaGenic’s partner in India, SRL Laboratories, has performed a thorough review of the test documentation, audited their subcontractor and independent studies with DiaGenic’s test to ensure adherence to quality standards at all levels of operations. All studies have successfully been concluded and both parties have now signed off the test for a commercial launch.

The launch date is set to November 8th. After 10...

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

9/18/2008 4:30 AM EST
On September 18 2008 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The primary insiders entered into a 6 month forward contract for the purchase of 410,000 shares at NOK 6.2356 per share. This contract is a continuation of the forward contract entered into on September 18 2007 for the same number of shares. The transactions made no changes in the net exposure among the insiders....

New certificate of registration

9/5/2008 4:13 AM EST
DiaGenic ASA has today received a new Certificate of Registration from the Register of Business Enterprises in connection with registry of the subscription right programme for employees and power of attorney to increase share capital as resolved by the annual general meeting on June 12.

This information is subject to disclosure requirements according to §5-12 vphl (Norwegian Securities Trading Act).

Contact:...

DiaGenic ASA

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early in...

View more


  CONTACT